Ependymoma Drug Market
According to Intent Market Research, the Ependymoma Drug Market is expected to grow from USD 0.2 billion in 2023 at a CAGR of 4.2% to touch USD 0.3 billion by 2030. The Ependymoma Drug Market is dominated by key players such as Bristol-Myers Squibb, Roche, Merck & Co., Novartis, Pfizer Inc., Eli Lilly and Company, Bayer AG, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Amgen Inc., Takeda Pharmaceutical Company, AbbVie Inc., Biogen Inc., Sanofi